Literature DB >> 23183524

Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection.

Matthew T Kitson1, Gregory J Dore, Jacob George, Peter Button, Geoffrey W McCaughan, Darrell H G Crawford, William Sievert, Martin D Weltman, Wendy S Cheng, Stuart K Roberts.   

Abstract

BACKGROUND & AIMS: The relationship between vitamin D status and response to antiviral therapy and liver histology in hepatitis C virus genotype 1 (HCV-1) infection remains unclear, with studies to date yielding inconsistent results and failing to use reference assay methodology. We therefore analyzed pre-treatment 25-hydroxyvitamin D [25(OH)D] level, using reference liquid chromatography-tandem mass spectrometry methodology, in a cohort of treatment-naïve patients with HCV-1 to evaluate the association between vitamin D status, virologic response, and liver histology.
METHODS: 274 patients, with pre-treatment liver biopsy and up to 48 weeks of pegylated interferon alfa-2a plus ribavirin therapy, were tested for serum 25(OH)D level. Predictors of sustained virologic response (SVR), and variables associated with fibrosis stage, activity grade and 25(OH)D status were identified using multivariate analysis.
RESULTS: Mean 25(OH)D level was 79.6 nmol/L, with a prevalence of 25(OH)D <75 nmol/L and <50 nmol/L of 48% and 16%, respectively. Season, race and geographic latitude were independent predictors of 25(OH)D status, while vitamin D deficiency was more prevalent in those with high activity grade (21% vs. 11%; p=0.03). Mean 25(OH)D level was lower (76.6 vs. 84.7 nmol/L; p=0.03) and 25(OH)D <75 nmol/L more prevalent (53% vs. 40%; p=0.03) in patients with an SVR, but no association between 25(OH)D status and SVR was found in multivariate analysis. Mean 25(OH)D level did not vary between fibrosis stage or activity grade.
CONCLUSIONS: Baseline 25(OH)D level is not independently associated with SVR or fibrosis stage in HCV-1, but vitamin D deficiency is associated with high activity grade.
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23183524     DOI: 10.1016/j.jhep.2012.11.017

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  32 in total

Review 1.  Osteoporosis across chronic liver disease.

Authors:  M Guarino; I Loperto; S Camera; V Cossiga; C Di Somma; A Colao; N Caporaso; F Morisco
Journal:  Osteoporos Int       Date:  2016-02-04       Impact factor: 4.507

Review 2.  Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.

Authors:  Tzu-Hao Lee; Hans L Tillmann; Keyur Patel
Journal:  Mol Diagn Ther       Date:  2014-02       Impact factor: 4.074

3.  25-OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV-infected patients.

Authors:  Arthur Belle; Emmanuel Gizard; Guillaume Conroy; Anthony Lopez; Magali Bouvier-Alias; Stéphanie Rouanet; Laurent Peyrin-Biroulet; Jean-Michel Pawlotsky; Jean-Pierre Bronowicki
Journal:  United European Gastroenterol J       Date:  2016-07-07       Impact factor: 4.623

4.  Vitamin D status and viral response to therapy in hepatitis C infected children.

Authors:  Azza A Eltayeb; Madleen Adel A Abdou; Amal M Abdel-aal; Mostafa H Othman
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

Review 5.  Vitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirin.

Authors:  Bassem Refaat; Adel Galal El-Shemi; Ahmed Ashshi; Esam Azhar
Journal:  Int J Clin Exp Med       Date:  2015-07-15

6.  Severe Vitamin D Deficiency Is Not Associated with Liver Damage in Morbidly Obese Patients.

Authors:  Rodolphe Anty; Audrey Hastier; Clémence M Canivet; Stéphanie Patouraux; Anne-Sophie Schneck; Patricia Ferrari-Panaia; Imed Ben-Amor; Marie Christine Saint-Paul; Jean Gugenheim; Philippe Gual; Antonio Iannelli; Albert Tran
Journal:  Obes Surg       Date:  2016-09       Impact factor: 4.129

Review 7.  Association between serum vitamin D and severity of liver fibrosis in chronic hepatitis C patients: a systematic meta-analysis.

Authors:  Yue-qiu Luo; Xiao-xing Wu; Zong-xin Ling; Yi-wen Cheng; Li Yuan; Charlie Xiang
Journal:  J Zhejiang Univ Sci B       Date:  2014-10       Impact factor: 3.066

8.  Serum vitamin D₃ does not correlate with liver fibrosis in chronic hepatitis C.

Authors:  Yan Ren; Mei Liu; Jing Zhao; Feng Ren; Yu Chen; Jun-Feng Li; Jing-Yun Zhang; Feng Qu; Jin-Lan Zhang; Zhong-Ping Duan; Su-Jun Zheng
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

9.  The association between serological and dietary vitamin D levels and hepatitis C-related liver disease risk differs in African American and white males.

Authors:  D L White; S Tavakoli-Tabasi; F Kanwal; D J Ramsey; A Hashmi; J Kuzniarek; P Patel; J Francis; H B El-Serag
Journal:  Aliment Pharmacol Ther       Date:  2013-05-26       Impact factor: 8.171

10.  In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use.

Authors:  Andrea D Branch; Minhee Kang; Kimberly Hollabaugh; Christina M Wyatt; Raymond T Chung; Marshall J Glesby
Journal:  Am J Clin Nutr       Date:  2013-06-05       Impact factor: 7.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.